TY - JOUR
T1 - Multicenter epidemiology of Stenotrophomonas maltophilia bloodstream infections in Indian ICUs
T2 - building digital surveillance network
AU - Singh, Parul
AU - Ahmed, M. Nizam
AU - Srivastava, Ashish Kumar
AU - Thakur, Arpan Kumar
AU - Parveen, Rasna
AU - Puraswani, Mamta
AU - Kumar, Subodh
AU - Sagar, Sushma
AU - Soni, Kapil Dev
AU - Aggarwal, Richa
AU - Bindra, Ashish
AU - Goyal, Keshav
AU - Farooque, Kamran
AU - Chakrabarti, Arunaloke
AU - Rodrigues, Camilla
AU - Balaji, Veeraraghavan
AU - Ray, Pallab
AU - Biswal, Manisha
AU - Taneja, Neelam
AU - Angrup, Archana
AU - Wattal, Chand
AU - Venkatesh, Vimala
AU - Sethuraman, Nandini
AU - Bhattacharya, Sanjay
AU - Tak, Vibhor
AU - Behera, Bijayini
AU - Hallur, Vinaykumar
AU - Ray, Raja
AU - Rudramurthy, Shivaprakash M.
AU - Sehgal, Inderpaul
AU - Singh, Sanjeev K.
AU - Gupta, Sharmila Sen
AU - Mukhopadhyay, Chiranjay
AU - Michael, Joy Sarojini
AU - Fomda, Bashir Ahmad
AU - Karuna, Tadepalli
AU - Deotale, Vijayshri
AU - Prasad, Amber
AU - Padmaja, Kanne
AU - Bajpai, Vijeta
AU - Nath, Reema
AU - Gur, Renu
AU - Devi, Sheela
AU - Malhotra, Shalini
AU - Gaind, Rajni
AU - Khuraijam, Ranjana Devi
AU - Sharma, Rajni
AU - Mullan, Summaiya
AU - Prakash, John Antony Jude
AU - Paul, Hema
AU - Rupali, Priscilla
AU - Verma, Sheetal
AU - Rajdev, Sangita
AU - Goel, Neeraj
AU - Chelliah, Juliah
AU - Mukherjee, Satyam
AU - Sonowal, Aparna
AU - Kumari, Veena
AU - Verma, Prachi
AU - KE, Vandana
AU - Mane, Manisha Subrao
AU - Majumder, Tapan
AU - Walia, Kamini
AU - Mathur, Purva
N1 - Publisher Copyright:
Copyright © 2025 Singh, Ahmed, Srivastava, Thakur, Parveen, Puraswani, Kumar, Sagar, Soni, Aggarwal, Bindra, Goyal, Farooque, Chakrabarti, Rodrigues, Balaji, Ray, Biswal, Taneja, Angrup, Wattal, Venkatesh, Sethuraman, Bhattacharya, Tak, Behera, Hallur, Ray, Rudramurthy, Sehgal, Singh, Gupta, Mukhopadhyay, Michael, Fomda, Karuna, Deotale, Prasad, Padmaja, Bajpai, Nath, Gur, Devi, Malhotra, Gaind, Khuraijam, Sharma, Mullan, Prakash, Paul, Rupali, Verma, Rajdev, Goel, Chelliah, Mukherjee, Sonowal, Kumari, Verma, KE, Mane, Majumder, Walia and Mathur.
PY - 2025
Y1 - 2025
N2 - Background: To investigate the geospatial epidemiology, clinical features, treatment patterns, and antimicrobial resistance (AMR) trends of Stenotrophomonas maltophilia bloodstream infections (BSIs) in Indian intensive care units (ICUs) participating in a standardized healthcare-associated infection (HAI) surveillance program from 2017 to 2024. Methods: This retrospective, multicentric study analyzed surveillance data from 54 ICUs across India. Standardized HAI definitions and protocols were applied to characterize infection types, clinical outcomes, and antimicrobial susceptibility. Results: A total of 271 S. maltophilia isolates were identified, with the highest burden in 2023–24 (n = 76, 28.0%). Central line-associated BSIs (CLABSIs) predominated (64.9%), though their proportion decreased over time, with non-CLABSIs rising from 7.4% (2017–18) to 42.1% (2023–24). Mortality was highest in secondary BSIs (60%), followed by CLABSIs (50.3%) and non-CLABSIs (36.4%). The median ICU stay for CLABSI patients was 21 days. No significant associations were observed between infection type and time to infection or length of stay. High resistance was observed to tobramycin (92%), amikacin (80%), and piperacillin-tazobactam (70%), while trimethoprim-sulfamethoxazole (64.7–94.7%), levofloxacin (93%), and minocycline (94.1%) retained activity. Conclusion: S. maltophilia represents a significant ICU pathogen in India, underscoring the urgent need for genomic surveillance and resistance-guided therapeutic strategies.
AB - Background: To investigate the geospatial epidemiology, clinical features, treatment patterns, and antimicrobial resistance (AMR) trends of Stenotrophomonas maltophilia bloodstream infections (BSIs) in Indian intensive care units (ICUs) participating in a standardized healthcare-associated infection (HAI) surveillance program from 2017 to 2024. Methods: This retrospective, multicentric study analyzed surveillance data from 54 ICUs across India. Standardized HAI definitions and protocols were applied to characterize infection types, clinical outcomes, and antimicrobial susceptibility. Results: A total of 271 S. maltophilia isolates were identified, with the highest burden in 2023–24 (n = 76, 28.0%). Central line-associated BSIs (CLABSIs) predominated (64.9%), though their proportion decreased over time, with non-CLABSIs rising from 7.4% (2017–18) to 42.1% (2023–24). Mortality was highest in secondary BSIs (60%), followed by CLABSIs (50.3%) and non-CLABSIs (36.4%). The median ICU stay for CLABSI patients was 21 days. No significant associations were observed between infection type and time to infection or length of stay. High resistance was observed to tobramycin (92%), amikacin (80%), and piperacillin-tazobactam (70%), while trimethoprim-sulfamethoxazole (64.7–94.7%), levofloxacin (93%), and minocycline (94.1%) retained activity. Conclusion: S. maltophilia represents a significant ICU pathogen in India, underscoring the urgent need for genomic surveillance and resistance-guided therapeutic strategies.
UR - https://www.scopus.com/pages/publications/105025546800
UR - https://www.scopus.com/pages/publications/105025546800#tab=citedBy
U2 - 10.3389/fmicb.2025.1725629
DO - 10.3389/fmicb.2025.1725629
M3 - Article
AN - SCOPUS:105025546800
SN - 1664-302X
VL - 16
JO - Frontiers in Microbiology
JF - Frontiers in Microbiology
M1 - 1725629
ER -